Telehealth coaching to improve life quality for pancreatic cancer survivors and their caregivers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of telehealth self-management coaching sessions aimed at enhancing the quality of life for survivors of metastatic pancreatic adenocarcinoma and their family caregivers. The program addresses various aspects of well-being, including physical, emotional, social, and spiritual health, which are often compromised due to the disease and its treatment. By providing support through telemedicine, the study seeks to meet the unmet needs of patients and their families during a challenging time. Participants will engage in counseling and complete questionnaires to assess the impact of the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • PATIENT: Documented informed consent of the participant and/or legally authorized representative

  * Assent, when appropriate, will be obtained per institutional guidelines

    * PATIENT: Age: ≥ 18 years
    * PATIENT: Eastern Cooperative Oncology Group (ECOG) ≤ 2
    * PATIENT: Ability to read and understand English or Spanish for questionnaires
    * PATIENT: Subjects must have histologically or cytologically confirmed diagnosis of metastatic pancreatic adenocarcinoma who are within 8 weeks of initial diagnosis
    * FAMILY CARE GIVER: Documented informed consent of the participant and/or legally authorized representative
  * Assent, when appropriate, will be obtained per institutional guidelines

    * FAMILY CARE GIVER: Age: ≥ 18 years
    * FAMILY CARE GIVER: Ability to read and understand English or Spanish for questionnaires
    * FAMILY CARE GIVER: A family member or friend identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care

Exclusion Criteria:

* • An employee who is under the direct/ indirect supervision of the principal investigator (PI)/ a co-investigator/ the study manager

  * A direct study team member

Where it's running

• City of Hope at Duarte
  Duarte, California, United States Recruiting
• City of Hope at Arcadia
  Arcadia, California, United States Not yet recruiting
• City of Hope Corona
  Corona, California, United States Not yet recruiting
• City of Hope Comprehensive Cancer Center
  Duarte, California, United States Not yet recruiting
• City of Hope at Glendale
  Glendale, California, United States Not yet recruiting
• City of Hope at Glendora
  Glendora, California, United States Not yet recruiting

Study contacts

• Principal investigator: Vincent Chung, MD — City of Hope Medical Center
• Study coordinator: Vincent Chung, MD
• Email: vchung@coh.org
• Phone: 626-359-8111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• Setidegrasib with mFOLFIRINOX or NALIRIFOX for KRAS G12D metastatic pancreatic cancer

  This trial tests whether adding setidegrasib to mFOLFIRINOX or NALIRIFOX helps people with metastatic pancreatic cancer who have a KRAS G12D mutation.

  Recruiting at 104 sites Phase 3 Astellas Pharma Inc · Gilbert, Arizona and 103 other locations · NCT07409272

• BMS-986340 with nivolumab plus gemcitabine and nab-paclitaxel for advanced or recurrent pancreatic adenocarcinoma

  This trial tests whether adding the antibody BMS-986340 to nivolumab together with gemcitabine and nab-paclitaxel helps people with metastatic or recurrent pancreatic adenocarcinoma.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT07226856

• TR-002 (Nadofaragene Firadenovec) given by IV for adults with advanced unresectable or metastatic solid tumors and refractory metastatic pancreatic adenocarcinoma

  This Phase 1 trial tests whether weekly intravenous TR-002 is safe and what dose is best for adults with advanced unresectable or metastatic solid tumors or refractory metastatic pancreatic cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT07189195

• Comparing NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen for advanced pancreatic adenocarcinoma

  This compares NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen to see if it helps people with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma live longer or have better tumor responses.

  Recruiting at 2 sites Phase 2 Medical University of South Carolina · Charleston, South Carolina and 1 other locations · NCT07076212

• Adding panitumumab to chemotherapy for unresectable or metastatic KRAS wild-type pancreatic cancer

  This trial will test whether giving the antibody panitumumab along with standard chemotherapy helps people with unresectable, locally advanced, or metastatic KRAS wild-type pancreatic cancer live longer.

  Recruiting at 272 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 273 other locations · NCT06998940

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.